1 |
Iliescu EL, Mercan-Stanciu A, Toma L, Ioanitescu ES, Dumitru R, Rusie D. Hepatocellular carcinoma in the setting of interferon free treatment for chronic HCV hepatitis - experience of a single center. Hepatoma Res 2018;4:3.
DOI
|
2 |
Abd-Elgawad MM, Baddour NM, Salem MA. Chronic hepatitis C in children: clinical spectrum and histopathological study. Alexandria Journal of Medicine 2013;49:363-8.
DOI
|
3 |
El-Guindi MA. Hepatitis C viral infection in children: updated review. Pediatr Gastroenterol Hepatol Nutr 2016;19:83-95.
DOI
|
4 |
Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012;54:838-55.
DOI
|
5 |
Stallings-Smith S, Krull KR, Brinkman TM, Hudson MM, Ojha RP. Longterm follow-up for incident cirrhosis among pediatric cancer survivors with hepatitis C virus infection. J Clin Virol 2015;71:18-21.
DOI
|
6 |
Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World J Gastroenterol 2012;18:99-104.
DOI
|
7 |
Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007;196:1474-82.
DOI
|
8 |
Wiersinga WM. Guidance in subclinical hyperthyroidism and subclinical hypothyroidism: are we making progress? Eur Thyroid J 2015;4:143-8.
DOI
|
9 |
Tomer Y, Menconi F. Interferon induced thyroiditis. Best Pract Res Clin Endocrinol Metab 2009;23:703-12.
DOI
|
10 |
Moncoucy X, Leymarie F, Delemer B, Levy S, Bernard-Chabert B, Bouche O, et al. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005;29:339-45.
DOI
|
11 |
Andrade LJ, Atta AM, D'Almeida Junior A, Parana R. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review. Braz J Infect Dis 2008;12:144-8.
DOI
|
12 |
Carella C, Mazziotti G, Morisco F, Manganella G, Rotondi M, Tuccillo C, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab 2001;86:1925-9.
DOI
|
13 |
World Health Organization. Global hepatitis [Internet]. Geneva (Switzerland): World Health Organization, 2007.
|
14 |
Vasiliadis T, Anagnostis P, Nalmpantidis G, Soufleris K, Patsiaoura K, Grammatikos N, et al. Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C. Ann Acad Med Singapore 2011;40:394-400.
|
15 |
Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-6.
DOI
|
16 |
Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, et al. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999;141:325-31.
DOI
|
17 |
El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2002;36:1439-45.
DOI
|
18 |
Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004;117:10-3.
DOI
|
19 |
Floreani A, Betterle C, Carderi I, Presotto F, Pedini B, Moscon A, et al. Is hepatitis C virus a risk factor for thyroid autoimmunity? J Viral Hepat 2006;13:272-7.
DOI
|